Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

As a result, Hims & Hers will soon have to limit its previous offerings of the drug. Last May, the company began selling compounded semaglutide ... taking the highest dose of Eli Lilly ...

But that figure excludes commercially available dosages of semaglutide, which the company will no longer offer after the first quarter, executives said. Hims & Hers said it would pivot to focus on ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though ...

Since parting ways with The Real Housewives of Orange County, Braunwyn Spinner has undergone a drastic physical and mental ...

Hims & Hers Health, Inc.'s share price surged when a global shortage of tirzepatide / semaglutide - a rival ... Lilly is offering a single dose vial of tirzepatide via its DTC platform for $ ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...

Their tight supply had allowed Hims & Hers and others to sell cheaper versions of Novo's semaglutide. Hims & Hers said in February it cannot guarantee to continue to sell compounded semaglutide ...

One of the more hotly debated stocks in the market, Hims & Hers Health HIMS ... around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo ...